Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

Inclusion Criteria:

• Male and female patients of any age and ethnicity

• Severe haemophilia A (FVIII:C<1%)

• Decision to prescribe Octapharma's FVIII concentrate before enrollment into thestudy

• Either

• No previous treatment with FVIII concentrates or other blood products containingFVIII (PUPs) OR

• Less than 5 Exposure Days (EDs) to FVIII concentrates or other blood productscontaining FVIII (MTPs), if

• data are available on all previous treatment, AND

• they did not develop an inhibitor at any time point, OR

• they developed an inhibitor during treatment with an Octapharma FVIII concentrateAND continue treatment with THIS Octapharma FVIII concentrate (in the presence orabsence of emicizumab).

• Voluntarily given, fully informed written and signed consent obtained before anystudy-related data documentation is conducted (obtained from the patient'sparent/legal guardian)

Exclusion Criteria:

• Diagnosis with a coagulation disorder other than haemophilia A

• Concomitant treatment with any systemic immunosuppressive drug

• Participation in an interventional clinical trial during the time period evaluated

• Participation in another non-interventional study of Octapharma